Scorpio fuscus venom as a promising anticancer agent against colorectal cancer

dc.contributor.authorKarakurt, Serdar
dc.contributor.authorGokcek-Sarac, Cigdem
dc.contributor.authorKandir, Sinan
dc.contributor.authorBilgiseven, Irem Mukaddes
dc.contributor.authorYagmur, Ersen Aydin
dc.contributor.authorÇelebioğlu, Hasan Ufuk
dc.date.accessioned2026-02-22T11:43:58Z
dc.date.created2026
dc.date.issued2026
dc.departmentBartın Üniversitesi
dc.description.abstractColorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for novel and effective therapeutic agents. Conventional treatments, including chemotherapy, radiotherapy, and surgery, are often associated with significant adverse effects, prompting the exploration of alternative therapeutic strategies. This study aimed to evaluate the anticancer effects of Scorpio fuscus venom (SFV) on human colorectal cancer models using integrated in vitro and in vivo approaches. SFV constituents were characterized using gel electrophoresis, followed by high-performance liquid chromatography and UV-visible spectrometry. Identified peptides were subjected to structural modeling and in silico docking analyses against selected proteins associated with colorectal cancer and apoptosis-related pathways. The cytotoxic effects of SFV were assessed in human CRC cell lines (DLD-1, HT-29, and CaCo-2) and a healthy colon epithelial cell line (CCD-18Co) using Alamar Blue assays after 48-h treatment, and half-maximal inhibitory concentration (IC50) values were determined. SFV treatment resulted in a dose-dependent reduction in cancer cell viability, accompanied by decreased migratory capacity and colony formation ability. Apoptotic responses were further evaluated by flow cytometry and gene expression analyses, indicating modulation of apoptosis-associated genes. For in vivo validation, subcutaneous and orthotopic xenograft colon cancer models were established in mice. SFV administration led to reduced tumor growth compared with control groups. Immunohistochemical analyses revealed altered expression patterns of selected tumor-related markers in SFV-treated tumors. Gene expression profiling demonstrated >= twofold changes in 51 genes, including downregulation of BAK1 and TRAF3, and upregulation of BIRC2, BIRC3, BIRC6, CASP8, TNFRSF8, TNFRSF11, and BOK. Collectively, these findings indicate that SFV exerts significant antitumor effects in colorectal cancer models and support its potential as a promising anticancer agent, warranting further mechanistic and translational investigation.
dc.description.sponsorshipSelcuk University; Seluk University Research Foundation [21401070]; Trkiye Bilimsel ve Teknolojik Arascedil;timath;rma Kurumu [120Z942]
dc.description.sponsorshipOpen access funding provided by the Scientific and Technological Research Council of Turkiye (TUB & Idot;TAK).
dc.identifier.doi10.1007/s10637-026-01598-z
dc.identifier.issn0167-6997
dc.identifier.issn1573-0646
dc.identifier.pmid41627596
dc.identifier.scopus2-s2.0-105029250652
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s10637-026-01598-z
dc.identifier.urihttps://hdl.handle.net/11772/26890
dc.identifier.wosWOS:001677088200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofInvestigational New Drugs
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260218
dc.subjectScorpio fuscus
dc.subjectVenom
dc.subjectColorectal carcinoma
dc.subjectIn vivo
dc.subjectMolecular mechanism
dc.subjectSignaling pathways
dc.titleScorpio fuscus venom as a promising anticancer agent against colorectal cancer
dc.typeArticle
dspace.entity.typePublication

Dosyalar